
Dermatology
Latest News
Latest Videos

CME Content
More News

Full video: Experts discuss the overlap between immune-mediated inflammatory diseases in GI and dermatology, emphasizing the importance of cross-specialty care.

In the final segment of this HCPLive Special Report, experts discuss lingering unmet needs in cross-specialty care and look ahead to potential areas for improvement.

In part 2 of their HCPLive Special Report series, Raj Chovatiya, MD, PhD, and Adelina Hung, MD, continue their in-depth conversation.

In this HCPLive Special Report series, Raj Chovatiya, MD, PhD, and Adelina Hung, MD, discuss the connection between GI and dermatologic care.

Leading experts discuss managing atopic dermatitis in skin of color in a live recording from the 2025 Revolutionizing Atopic Dermatitis Conference.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 notable dermatology updates from the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference.

This analysis highlights the risk of superficial fungal infections among patients with moderate-to-severe psoriasis given biologics such as IL-17 inhibitors.

This update by FDA officials extends the review period for ruxolitinib cream as a treatment for atopic dermatitis in children aged 2-11 years.

These data from RAD 2025 highlight upadacitinib’s efficacy in the phase 3 Measure Up 1 and 2 studies for older adults with atopic dermatitis.

This Q&A interview at RAD 2025 features a discussion about a talk titled ‘Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis.’

Dupilumab (Dupixent) approved as the first targeted therapy for bullous pemphigoid, marking 8th indication for diseases with type 2 inflammation.

Melinda Gooderham, MD, MSc, joins The Medical Sisterhood to discuss balancing mentorship, leadership, and family, as well as the empowerment of women in the medical field.

This analysis highlights the observed risk of developing psoriasis when using dupilumab to treat atopic dermatitis.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.

This June 17, 2025 SOCS News Update highlights creating strategic plans with mentors and mentees.

The FDA-cleared DermaSensor shows promise for skin cancer detection in primary care.

Recent research comparing the two diseases against a sample of the general population has indicated a substantially higher mortality risk and rate in GPP than in plaque psoriasis.

These data highlight the adverse events resulting from the use of dutasteride and finasteride in treating androgenetic alopecia.

Study findings highlight a heightened risk of MetS in patients with psoriasis, especially those with more severe disease based on PASI scores.

Research has indicated a suggestive association between predicted psoriasis and uterine corpus cancer in women and prostate cancer in men.

This interview at RAD 2025 highlights a session on dose flexibility in adult patients with atopic dermatitis, presented by Tejesh Patel, MD.



















































